Trial Profile

An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naive Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Feb 2017 According to an Enanta Pharmaceuticals media release, the Committee for Medicinal Products for Human Use (CHMP) of the EMA has granted a positive opinion for an eight-week treatment regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) + EXVIERA (dasabuvir) as an option for previously untreated adult patients with genotype 1b (GT1b) chronic HCV infection and minimal to moderate fibrosis based on data from this trial.
01 Dec 2016 Status changed from active, no longer recruiting to completed.
31 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com